Sotagliflozin Reduces Risk for Adverse CV Events in Diabetic Kidney Disease
Sotagliflozin might help patients with diabetes and chronic kidney disease who are hospitalized with heart failure avoid a readmission, study results suggest.
All articles by Natasha Persaud
Elevated FGF23 Linked to Mortality in Type 2 Diabetes
In a study, elevated FGF23 was associated with increased risks of major adverse cardiovascular events and mortality in type 2 diabetes patients with normal or mildly impaired kidney function.
-
Loading...
-
Loading...
Next post in Type 2 Diabetes
